Disease · MONDO_0004948
Comparisons in its trials184
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 184
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Fludarabine+Cyclophosphamide (FC) vs Fludarabine+Cyclophosphamide+Rituximab (FCR): serious adverse events | 164 of 398 | 186 of 402 | 800 | NCT00281918 | Trial comparisons |
| Unselected Population (Participants With Any Comorbidity) vs Slow Go Subpopulation: serious adverse events | 85 of 485 | 44 of 196 | 681 | NCT01178086 | Trial comparisons |
| Rituximab + Chlorambucil (RClb) vs Obinutuzumab + Chlorambucil (GClb): serious adverse events | 124 of 321 | 150 of 336 | 657 | NCT02053610 | Trial comparisons |
| Zanubrutinib vs Ibrutinib: deaths from any cause | 69 of 327 | 83 of 325 | 652 | NCT03734016 | Trial comparisons |
| Zanubrutinib vs Ibrutinib: serious adverse events | 172 of 324 | 196 of 324 | 648 | NCT03734016 | Trial comparisons |
| Ibrutinib+BR vs Placebo+BR: Number of Participants With Clinically Relevant Shifts in Disease-Related Symptoms | 0 of 289 | 0 of 289 | 578 | NCT01611090 | Trial comparisons |
| Ibrutinib+BR vs Placebo+BR: Number of Participants Who Received Subsequent Antineoplastic Therapy | 52 of 287 | 61 of 287 | 574 | NCT01611090 | Trial comparisons |
| Fludarabine+Cyclophosphamide (FC) vs Fludarabine+Cyclophosphamide+Rituximab (FCR): serious adverse events | 132 of 272 | 138 of 274 | 546 | NCT00090051 | Trial comparisons |
| Arm A (Ibrutinib, Rituximab) vs Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide): deaths from any cause | 4 of 354 | 10 of 175 | 529 | NCT02048813 | Trial comparisons |
| Acalabrutinib vs Ibrutinib: Number of Participants With Treatment-emergent Richter's Transformation | 13 of 266 | 14 of 263 | 529 | NCT02477696 | Trial comparisons |
| Acalabrutinib vs Ibrutinib: Number of Participants With Treatment-emergent Atrial Fibrillation | 32 of 266 | 49 of 263 | 529 | NCT02477696 | Trial comparisons |
| Acalabrutinib vs Ibrutinib: Number of Participants With Treatment-emergent Infections Grade >= 3 | 98 of 266 | 101 of 263 | 529 | NCT02477696 | Trial comparisons |
| Acalabrutinib vs Ibrutinib: deaths from any cause | 89 of 266 | 106 of 263 | 529 | NCT02477696 | Trial comparisons |
| Acalabrutinib vs Ibrutinib: serious adverse events | 161 of 266 | 177 of 263 | 529 | NCT02477696 | Trial comparisons |
| Arm A (Ibrutinib, Rituximab) vs Arm B (Rituximab, Fludarabine Phosphate, Cyclophosphamide): serious adverse events | 270 of 352 | 132 of 158 | 510 | NCT02048813 | Trial comparisons |
| Ofatumumab vs Observation: Number of Participants Who Received at Least One Transfusion During the Study | 96 of 239 | 64 of 241 | 480 | NCT01039376 | Trial comparisons |
| Ofatumumab vs Observation: Number of Participants With Grade 3 and Above Adverse Event of Infection | 38 of 239 | 23 of 241 | 480 | NCT01039376 | Trial comparisons |
| Lenalidomide vs Chlorambucil: Number of Participants Deaths During the Treatment and Survival Follow-Up Phase | 101 of 225 | 95 of 225 | 450 | NCT00910910 | Trial comparisons |
| Lenalidomide vs Chlorambucil: deaths from any cause | 100 of 224 | 93 of 223 | 447 | NCT00910910 | Trial comparisons |
| Lenalidomide vs Chlorambucil: serious adverse events | 148 of 224 | 90 of 223 | 447 | NCT00910910 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004948/comparisons